Finding the best adjuvants for a vaccine against Group A Streptococcus
Official title: Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models
Funded at University of California, San Diego · NIH-11003338 · Data updated 2026-11-12
This study is working on a new vaccine to help protect people from infections caused by Group A Streptococcus, especially for those who are more at risk, by testing different ingredients that can boost the vaccine's effectiveness.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | January 5, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $635,274 |
| NIH project number | 5R01AI173689-03 |
| Project ID | NIH-11003338 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and adults who are at risk of infections caused by Group A Streptococcus, particularly those with a history of rheumatic fever.
✕Less likely to help
Patients who are not at risk for Group A Streptococcus infections or those who have already been vaccinated against it may not benefit from this research.
What this research studies
This research focuses on developing a vaccine for Group A Streptococcus (GAS), a major bacterial pathogen responsible for numerous infections and serious health complications. The team will investigate different adjuvants, which are substances that enhance the body's immune response to the vaccine, using preclinical models in mice and nonhuman primates. By understanding how these adjuvants affect vaccine efficacy, the goal is to create a safe and effective vaccine that can prevent diseases caused by GAS, particularly in vulnerable populations. The research aims to address the urgent need for a GAS vaccine by exploring innovative approaches to improve immune responses.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective vaccine that significantly reduces the incidence of infections and autoimmune diseases caused by Group A Streptococcus.
How similar studies have gone: Previous research has shown promise in developing vaccines for similar bacterial pathogens, indicating that this approach could yield successful outcomes.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Nizet, Victor — University of California, San Diego
- Study coordinator: Nizet, Victor
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.